James McDowell, MD
Family Medicine · Macon, MONPI 1255370482
Payments from drug & device makers
Across 115 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$319
- Amgen$196
- Dexcom, Inc.$146
- Otsuka America Pharmaceutical, Inc.$135
- Pfizer$114
- Novo Nordisk$110
- plus $839 from 22 others
What the payments were for
- Food & beverage$1,84599%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 17 | $319 |
| Amgen | 12 | $196 |
| Dexcom, Inc. | 6 | $146 |
| Otsuka America Pharmaceutical, Inc. | 7 | $135 |
| Pfizer | 7 | $114 |
| Novo Nordisk | 7 | $110 |
| E.r. Squibb & Sons, L.L.C. | 7 | $86 |
| Johnson & Johnson | 5 | $74 |
| Sunovion Pharmaceuticals Inc. | 5 | $62 |
| Abbott | 3 | $62 |
| Amarin Pharma, Inc. | 4 | $55 |
| Astellas Pharma US Inc | 3 | $52 |
| Acadia Pharmaceuticals Inc | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Organogenesis Inc. | 5 | $46 |
| Electromed, Inc. | 5 | $43 |
| Novartis | 3 | $39 |
| Daiichi Sankyo Inc. | 2 | $33 |
| AstraZeneca | 2 | $32 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Grifols USA, LLC | 1 | $19 |
| Merck | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Integra Lifesciences Corporation | 1 | $16 |
| Lilly USA, LLC | 1 | $13 |
| GSK | 1 | $11 |
How this compares
$1,860 in reported general payments places this provider in the 70th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 435 | $186,636 |
| OzempicSemaglutide | 83 | $104,940 |
| FarxigaDapagliflozin Propanediol | 51 | $44,819 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 62 | $38,390 |
| JanuviaSitagliptin Phosphate | 35 | $35,336 |
| MounjaroTirzepatide | 28 | $33,150 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 103 | $32,497 |
| JardianceEmpagliflozin | 32 | $32,005 |
| XareltoRivaroxaban | 26 | $28,036 |
| TrulicityDulaglutide | 29 | $27,550 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 68 | $23,169 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $18,073 |
| AptiomEslicarbazepine Acetate | 26 | $16,378 |
| Spiriva RespimatTiotropium Bromide | 27 | $15,298 |
| MyrbetriqMirabegron | 72 | $14,988 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $114 | $219,133538 claims |
| Novo NordiskOzempic | $110 | $104,94083 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $32 | $63,972107 claims |
| Lilly USA, LLCMounjaro, Trulicity | $13 | $60,70157 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix, Arnuity Ellipta, Breo Ellipta | $11 | $60,085154 claims |
| MerckJanuvia, Belsomra | $18 | $40,83148 claims |
| Johnson & JohnsonXarelto | $74 | $28,03626 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $62 | $16,37826 claims |
| Astellas Pharma US IncMyrbetriq | $52 | $14,98872 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $17 | $14,29871 claims |
| AbbVieLinzess | $319 | $6,84413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Macon
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.